期刊
NEUROSURGERY CLINICS OF NORTH AMERICA
卷 23, 期 2, 页码 307-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.nec.2012.01.007
关键词
Temozolomide; Glioblastoma multiforme; BCNU wafers; Bevacizumab; NovoTTF-100A
资金
- American Brain Tumor Association
- Visionary Fund Grant
- Eli and Edythe Broad Stem Cell Research Center
- UCLA
This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme. Temozolomide has quickly become part of the standard of care for the modern treatment of stage IV glioblastoma multiforme since its approval in 2005. Yet despite its improvements from previous therapies, median survival remains approximately 15 months, with a 2-year survival rate of 8% to 26%. The mechanism of action of this chemotherapeutic agent, conferred advantages and limitations, treatment resistance and rescue, and potential targets of future research are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据